Biomarkers for immune therapy in melanoma.

Biomarkers for immune therapy in melanoma. Semin Cutan Med Surg. 2018 Jun;37(2):120-126 Authors: Johnson DB, Chon J, Johnson MR, Balko JM Abstract Immune checkpoint inhibitors have dramatically transformed melanoma treatment options. However, intrinsic and acquired resistance remain fundamental limitations to extending the benefits to all patients. Understanding molecular and clinical features that correlate with response to treatment (biomarkers) may unravel therapeutic resistance, assist in treatment decision-making, and facilitate drug development. An intensive effort to characterize these biomarkers is underway. Herein, we highlight promising molecular biomarkers involving the tumor microenvironment, host immune response, and microbiome. We particularly focus on anti-programmed death-1 (PD-1) therapy but will also briefly cover anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and novel combination therapies. PMID: 30040089 [PubMed - in process]
Source: Seminars in Cutaneous Medicine and Surgery - Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research